Ibodutant
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide
|
|
Clinical data | |
Routes of administration |
Oral |
Identifiers | |
ATC code | None |
PubChem | CID: 11527495 |
IUPHAR/BPS | 2117 |
ChemSpider | 9702281 |
UNII | 1H7RSQ28BJ |
Synonyms | 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide |
Chemical data | |
Formula | C37H48N4O4S |
Molecular mass | 644.866 g/mol |
|
|
|
|
(what is this?) (verify) |
Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015[update], it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.[1]
See also[edit]
References[edit]
- ^ "CLINICAL TRIALS DATABASE". Menarini Group. Retrieved 11 March 2015.
- H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541.
- S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome.". Drugs of the Future 33 (2): 111–115.
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |